Medical Director of Pennsylvania's Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins BioAffinity Technologies' Medical and Scientific Advisory Board and Incorporates CyPath Lung Into Medical Practice
Medical Director of Pennsylvania's Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins BioAffinity Technologies' Medical and Scientific Advisory Board and Incorporates CyPath Lung Into Medical Practice
Medical Director of Pennsylvania's Lung Innovations Network and The Lung Center at Penn Highlands Healthcare, Sandeep Bansal, M.D., Joins bioAffinity Technologies' Medical and Scientific Advisory Board and Incorporates CyPath Lung into Medical Practice
宾夕法尼亚州肺部创新网络和宾夕法尼亚高地医疗保健公司肺部中心医学总监，医学博士桑迪普·班萨尔加入了BioAffinity Technologies的医学和科学顾问委员会，并将Cypath Lung纳入医疗实践
SAN ANTONIO, Texas (Feb. 6, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer including CyPath Lung, today announced that Sandeep Bansal, M.D., Medical Director of Lung Innovations Network, has joined the Company's Medical and Scientific Advisory Board to provide expert advice and counsel on bioAffinity Technology products and research.
德克萨斯州圣安东尼奥（2024 年 2 月 6 日）— 生物亲和性技术, Inc.（纳斯达克股票代码：BIAF；BIAFW）是一家专注于通过无创检测来检测包括CyPath Lung在内的早期癌症的生物技术公司，今天宣布，医学总监桑迪普·班萨尔医学博士 肺部创新网络，已加入该公司 医学和科学顾问委员会 就 BioAffinity Technology 产品和研究提供专家建议和咨询。
Lung Innovations Network, a patient-centered practice that offers comprehensive lung care to over 10,000 patients in central and western Pennsylvania, will incorporate CyPath Lung into its practice to aid in the detection of early-stage lung cancer.
肺部创新网络是一家以患者为中心的诊所，为宾夕法尼亚州中部和西部的10,000多名患者提供全面的肺部护理，它将把CyPath Lung纳入其实践中，以帮助发现早期肺癌。
"As a clinician, I see hundreds of patients a year who can directly benefit from CyPath Lung, bioAffinity's patient-friendly, noninvasive test for lung cancer. As a researcher, I am excited about the Company's ongoing studies to advance CyPath Lung, as well as noninvasive tests for other lung diseases," Dr. Bansal said. "I look forward to contributing to bioAffinity's innovative approach to lung health by working with the Company's science team and the esteemed physicians and researchers who sit on its advisory board."
“作为临床医生，我每年为数百名患者看病，他们可以直接从CyPath Lung中受益，这是BioAffinity对患者友好、无创的肺癌检测。作为一名研究人员，我对该公司正在进行的推进CyPath Lung的研究以及针对其他肺部疾病的无创测试感到兴奋，” 班萨尔博士说。“我期待与BioAffinity的科学团队以及顾问委员会中受人尊敬的医生和研究人员合作，为BioAffinity的肺部健康创新方法做出贡献。”
Dr. Bansal has extensive experience in minimally invasive pulmonary procedures including navigational and robotic bronchoscopy, endobronchial ultrasound and chest sonography, argon plasma coagulation, cryotherapy, airway stenting, bronchoscopic lung volume reduction and indwelling pleural catheters. A principal investigator of multiple clinical research trials and a journal reviewer for several medical journals, he has been instrumental in developing a comprehensive lung center that allows a rapid assessment and management of healthcare needs based on the population characteristics and available resources. The model has been very successful in bringing advanced pulmonary services, including the latest technology and population health services, including a robust lung cancer screening program, to support the region's clinical needs.
Bansal博士在微创肺部手术方面拥有丰富的经验，包括导航和机器人支气管镜检查、支气管内超声和胸部超声检查、氩血浆凝固、冷冻疗法、气道支架置入、支气管镜肺容量减少和留置胸膜导管。作为多项临床研究试验的首席研究员和多份医学期刊的期刊审稿人，他在开发综合肺部中心方面发挥了重要作用，该中心允许根据人群特征和可用资源快速评估和管理医疗需求。该模式非常成功地提供了先进的肺部服务，包括最新的技术和人口健康服务，包括强大的肺癌筛查计划，以支持该地区的临床需求。
"Dr. Bansal is a highly regarded clinician and researcher who will be a strong addition to our stellar Medical and Scientific Advisory Board. His demonstrated commitment to saving lives and improving patients' quality of life through innovative therapies and his prodigious research are truly impressive," bioAffinity Technologies President and CEO Maria Zannes said. "The caliber of our Advisory Board is a testament to the commitment each physician has placed on bringing breakthrough technology to market in the battle against lung cancer and other diseases of the lung."
“班萨尔博士是一位备受推崇的临床医生和研究人员，他将成为我们出色的医学和科学顾问委员会的有力补充。BioAffinity Technologies总裁兼首席执行官玛丽亚·赞内斯说，他表现出的通过创新疗法挽救生命和改善患者生活质量的承诺以及他的出色研究确实令人印象深刻。“我们顾问委员会的才干证明了每位医生都致力于将突破性技术推向市场，以对抗肺癌和其他肺部疾病。”